Physician profile
Jonathan Kessler
NPI 1043503246
$1,146.76
in general payments reported to CMS, 2019-2025
20 companies · $435 in 2025
The $435 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $16.77 · 2021: $148 · 2022: $17.40 · 2023: $82.73 · 2024: $446 · 2025: $435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $965.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $964.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $329.53 | 2023-2025 | |
| Genentech USA, INC. | $148.09 | 2021 | |
| Merck Sharp & Dohme LLC | $83.53 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Amgen INC. | $80.17 | 2024-2025 | Evenity, Prolia, Repatha |
| Abbvie INC. | $51.26 | 2025 | |
| Glaxosmithkline, LLC. | $46.64 | 2023-2025 | Shingrix, Arexvy, Penmenvy |
| Phathom Pharmaceuticals, INC. | $45.01 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $40.44 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $39.68 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $35.53 | 2022-2025 | Mounjaro |
| Astellas Pharma US INC | $34.15 | 2024 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $31.39 | 2023-2025 | Eliquis |
| Astrazeneca Pharmaceuticals LP | $30.02 | 2024 | Airsupra |
| Abbott Laboratories | $27.50 | 2025 | Freestyle Libre 3 |
| Paratek Pharmaceuticals, INC. | $27.46 | 2024-2025 | Nuzyra, Xhance |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $23.34 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.55 | 2025 | Xifaxan |
| Cipher Pharmaceuticals US LLC | $19.82 | 2025 | Spinosad, Natroba |
| Biohaven Pharmaceuticals, INC. | $16.77 | 2020 | |
| Currax Pharmaceuticals LLC | $14.88 | 2024 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Kessler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.